These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

415 related articles for article (PubMed ID: 25935098)

  • 1. Polyquaternium-1-Preserved Travoprost 0.003% or Benzalkonium Chloride-Preserved Travoprost 0.004% for Glaucoma and Ocular Hypertension.
    Peace JH; Ahlberg P; Wagner M; Lim JM; Wirta D; Branch JD
    Am J Ophthalmol; 2015 Aug; 160(2):266-274.e1. PubMed ID: 25935098
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of a travoprost BAK-free formulation preserved with polyquaternium-1 with BAK-preserved travoprost in ocular hypertension or open-angle glaucoma.
    Gandolfi S; Paredes T; Goldberg I; Coote M; Wells A; Volksone L; Pillai MR; Stalmans I; Denis P;
    Eur J Ophthalmol; 2012; 22(1):34-44. PubMed ID: 22167541
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Travoprost 0.004% with and without benzalkonium chloride: a comparison of safety and efficacy.
    Lewis RA; Katz GJ; Weiss MJ; Landry TA; Dickerson JE; James JE; Hua SY; Sullivan EK; Montgomery DB; Wells DT; Bergamini MV;
    J Glaucoma; 2007 Jan; 16(1):98-103. PubMed ID: 17224758
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Duration of IOP reduction with travoprost BAK-free solution.
    Gross RL; Peace JH; Smith SE; Walters TR; Dubiner HB; Weiss MJ; Ochsner KI
    J Glaucoma; 2008; 17(3):217-22. PubMed ID: 18414108
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term effect of BAK-free travoprost on ocular surface and intraocular pressure in glaucoma patients after transition from latanoprost.
    Aihara M; Otani S; Kozaki J; Unoki K; Takeuchi M; Minami K; Miyata K
    J Glaucoma; 2012 Jan; 21(1):60-4. PubMed ID: 21278589
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A 6-week, double-masked, parallel-group study of the efficacy and safety of travoprost 0.004% compared with latanoprost 0:005%/timolol 0.5% in patients with primary open-angle glaucoma or ocular hypertension.
    Franks WA; Renard JP; Cunliffe IA; Rojanapongpun P
    Clin Ther; 2006 Mar; 28(3):332-9. PubMed ID: 16750448
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of benzalkonium chloride-free travoprost on intraocular pressure and ocular surface symptoms in patients with glaucoma previously on latanoprost: an open-label study.
    Lopes JF; Hubatsch DA; Amaris P
    BMC Ophthalmol; 2015 Nov; 15():166. PubMed ID: 26563363
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of a fixed combination of travoprost 0.004%/timolol 0.5% ophthalmic solution once daily for open-angle glaucoma or ocular hypertension.
    Schuman JS; Katz GJ; Lewis RA; Henry JC; Mallick S; Wells DT; Sullivan EK; Landry TA; Bergamini MV; Robertson SM
    Am J Ophthalmol; 2005 Aug; 140(2):242-50. PubMed ID: 16086946
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A 1-year study to compare the efficacy and safety of once-daily travoprost 0.004%/timolol 0.5% to once-daily latanoprost 0.005%/timolol 0.5% in patients with open-angle glaucoma or ocular hypertension.
    Topouzis F; Melamed S; Danesh-Meyer H; Wells AP; Kozobolis V; Wieland H; Andrew R; Wells D
    Eur J Ophthalmol; 2007; 17(2):183-90. PubMed ID: 17415690
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Travoprost 0.004%/timolol 0.5%-fixed combination with and without benzalkonium chloride: a prospective, randomized, doubled-masked comparison of safety and efficacy.
    Kitazawa Y; Smith P; Sasaki N; Kotake S; Bae K; Iwamoto Y
    Eye (Lond); 2011 Sep; 25(9):1161-9. PubMed ID: 21701528
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A three-month, multicenter, double-masked study of the safety and efficacy of travoprost 0.004%/timolol 0.5% ophthalmic solution compared to travoprost 0.004% ophthalmic solution and timolol 0.5% dosed concomitantly in subjects with open angle glaucoma or ocular hypertension.
    Hughes BA; Bacharach J; Craven ER; Kaback MB; Mallick S; Landry TA; Bergamini MV
    J Glaucoma; 2005 Oct; 14(5):392-9. PubMed ID: 16148589
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Late-day intraocular pressure-lowering efficacy and tolerability of travoprost 0.004% versus bimatoprost 0.01% in patients with open-angle glaucoma or ocular hypertension: a randomized trial.
    DuBiner HB; Hubatsch DA
    BMC Ophthalmol; 2014 Nov; 14():151. PubMed ID: 25432143
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The safety and efficacy of travoprost 0.004%/timolol 0.5% fixed combination ophthalmic solution.
    Barnebey HS; Orengo-Nania S; Flowers BE; Samples J; Mallick S; Landry TA; Bergamini MV
    Am J Ophthalmol; 2005 Jul; 140(1):1-7. PubMed ID: 15990081
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ocular hypotensive efficacy of bimatoprost 0.03% and travoprost 0.004% in patients with glaucoma or ocular hypertension.
    Cantor LB; WuDunn D; Cortes A; Hoop J; Knotts S
    Surv Ophthalmol; 2004 Mar; 49 Suppl 1():S12-8. PubMed ID: 15016557
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A 6-week, multicenter, randomized, double-masked, parallel-group study comparing travoprost 0.004% to latanoprost 0.005% followed by 6-week, open-label treatment with travoprost 0.004%.
    Maul E; Carrasco FG; Costa VP; Casiraghi JF; Vargas E; Sarmina JS; Mayol R
    Clin Ther; 2007 Sep; 29(9):1915-23. PubMed ID: 18035191
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of topical travoprost eye drops given once daily and timolol 0.5% given twice daily in patients with open-angle glaucoma or ocular hypertension.
    Goldberg I; Cunha-Vaz J; Jakobsen JE; Nordmann JP; Trost E; Sullivan EK;
    J Glaucoma; 2001 Oct; 10(5):414-22. PubMed ID: 11711841
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of SofZia-preserved travoprost and benzalkonium chloride-preserved latanoprost on the ocular surface -- a multicentre randomized single-masked study.
    Aihara M; Oshima H; Araie M;
    Acta Ophthalmol; 2013 Feb; 91(1):e7-e14. PubMed ID: 23241328
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of the ocular hypotensive efficacy of adjunctive brimonidine 0.15% or brinzolamide 1% in combination with travoprost 0.004%.
    Feldman RM; Tanna AP; Gross RL; Chuang AZ; Baker L; Reynolds A; Prager TC;
    Ophthalmology; 2007 Jul; 114(7):1248-54. PubMed ID: 17509688
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of Switching to Travoprost Preserved With SofZia in Glaucoma Patients With Chronic Superficial Punctate Keratitis While Receiving BAK-preserved Latanoprost.
    Aihara M; Ikeda Y; Mizoue S; Arakaki Y; Kita N; Kobayashi S;
    J Glaucoma; 2016 Jun; 25(6):e610-4. PubMed ID: 25967526
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of latanoprost, bimatoprost, and travoprost on circadian variation of intraocular pressure in patients with open-angle glaucoma.
    Yildirim N; Sahin A; Gultekin S
    J Glaucoma; 2008; 17(1):36-9. PubMed ID: 18303382
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.